Some speculations on the myeloproliferative syndromes, Blood, vol.6, pp.372-375, 1951. ,
International Agency for Research on Cancer & World Health Organization. WHO classification of tumours of haematopoietic and lymphoid tissues, International Agency for Research on Cancer, 2008. ,
Chromosome studies on normal and leukemic human leukocytes, J. Natl. Cancer Inst, vol.25, pp.85-109, 1960. ,
A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining, Nature, vol.71, issue.5405, pp.290-293, 1973. ,
DOI : 10.1038/243290a0
The Myeloproliferative Disorders, New England Journal of Medicine, vol.355, issue.23, pp.2452-2466, 2006. ,
DOI : 10.1056/NEJMra063728
Oncogenic mechanisms in myeloproliferative disorders, Cellular and Molecular Life Sciences, vol.63, issue.24 ,
DOI : 10.1007/s00018-006-6272-7
Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics, Nature Reviews Clinical Oncology, vol.133, issue.11, pp.627-637, 2009. ,
DOI : 10.1038/nrclinonc.2009.149
Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period, British Journal of Haematology, vol.96, issue.1 ,
DOI : 10.1046/j.1365-2141.1997.d01-1982.x
Philadelphia (Ph) chromosome-positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood: natural history and diagnostic differentiation from Ph-negative essential thrombocythemia, Annals of Hematology, vol.83, issue.8, pp.504-512, 2004. ,
DOI : 10.1007/s00277-004-0877-4
BCR?ABL transcripts in bone marrow aspirates of Philadelphia?negative essential thrombocytopenia patients: clinical presentation, Blood, vol.90, pp.2768-2771, 1997. ,
Essential thrombocythemia with the Philadelphia chromosome and BCR-ABL gene rearrangement, Cancer Genetics and Cytogenetics, vol.54, issue.1, pp.21-25, 1991. ,
DOI : 10.1016/0165-4608(91)90025-P
Philadelphia chromosome-positive thrombocythemia without features of chronic myeloid leukemia (CML) in peripheral blood, Annals of Hematology, vol.83, issue.6, pp.409-410, 2005. ,
DOI : 10.1007/s00277-004-0993-1
Chronic myeloid leukemia with thrombocythemic onset may be associated with different BCR/ABL variant transcripts, Cancer Genetics and Cytogenetics, vol.101, issue.1, pp.75-77, 1998. ,
DOI : 10.1016/S0165-4608(97)00263-X
Typical essential thrombocythaemia does not express bcr-abelson fusion transcript, British Journal of Haematology, vol.14, issue.4, pp.812-816, 2002. ,
DOI : 10.1093/jjco/hyd122
Might essential thrombocythemia carry Ph anomaly? Blood 91, pp.3084-3085, 1998. ,
Every case of essential thrombocythemia should be tested for the Philadelphia chromosome, American Journal of Hematology, vol.98, issue.1, pp.71-73, 2005. ,
DOI : 10.1002/ajh.20257
Philadelphia Chromosome???Negative Chronic Myeloproliferative Disease, American Journal of Clinical Pathology, vol.132, issue.2 ,
DOI : 10.1309/AJCPR8GINMBDG9YG
A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders, Leukemia & Lymphoma, vol.63, issue.3, pp.381-396, 2006. ,
DOI : 10.1034/j.1600-0609.2002.02734.x
Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis, Haematologica, vol.89, pp.1194-1198, 2004. ,
Standardization and comparison of endogenous erythroid colony assays performed with bone marrow or blood progenitors for the diagnosis of polycythemia vera, The Hematology Journal, vol.5, issue.2, pp.161-167, 2004. ,
DOI : 10.1038/sj.thj.6200344
Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders, Leukemia, vol.110, issue.5, pp.905-914, 2008. ,
DOI : 10.1038/leu.2008.72
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia, The American Journal of Medicine, vol.117, issue.10, pp.755-761, 2004. ,
DOI : 10.1016/j.amjmed.2004.06.032
A standardized endogenous megakaryocytic erythroid colony assay for the diagnosis of essential thrombocythemia, Haematologica, vol.89, pp.1207-1212, 2004. ,
Patterns of Survival Among Patients With Myeloproliferative Neoplasms Diagnosed in Sweden From 1973 to 2008: A Population-Based Study, Journal of Clinical Oncology, vol.30, issue.24 ,
DOI : 10.1200/JCO.2012.42.1925
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment, Blood, vol.113, issue.13, pp.2895-2901, 2009. ,
DOI : 10.1182/blood-2008-07-170449
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome, Science, vol.247, issue.4944, pp.824-830, 1990. ,
DOI : 10.1126/science.2406902
Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates, European Journal of Haematology, vol.66, issue.3, pp.197-200, 2008. ,
DOI : 10.1002/ajh.2830110105
Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance, European Journal of Haematology, vol.255, issue.1, pp.17-21, 2009. ,
DOI : 10.1111/j.1600-0609.2009.01246.x
DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status, Journal of Clinical Oncology, vol.29, issue.4, pp.392-397, 2011. ,
DOI : 10.1200/JCO.2010.32.2446
World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management, American Journal of Hematology, vol.72, issue.3, pp.325-337, 2014. ,
DOI : 10.1002/ajh.23664
How we diagnose and treat WHO-defined systemic mastocytosis in adults, Haematologica, vol.93, issue.1, pp.6-9, 2008. ,
DOI : 10.3324/haematol.12324
Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera, Experimental Hematology, vol.32, issue.2, pp.179-187, 2004. ,
DOI : 10.1016/j.exphem.2003.11.003
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera, Nature, vol.100, issue.7037, pp.1144-1148, 2005. ,
DOI : 10.1182/blood-2002-09-2839
in Myeloproliferative Disorders, New England Journal of Medicine, vol.352, issue.17, pp.1779-1790, 2005. ,
DOI : 10.1056/NEJMoa051113
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders, The Lancet, vol.365, issue.9464, pp.1054-1061, 2005. ,
DOI : 10.1016/S0140-6736(05)74230-6
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis, Cancer Cell, vol.7, issue.4, pp.387-397, 2005. ,
DOI : 10.1016/j.ccr.2005.03.023
The Pseudokinase Domain Is Required for Suppression of Basal Activity of Jak2 and Jak3 Tyrosine Kinases and for Cytokine-inducible Activation of Signal Transduction, Journal of Biological Chemistry, vol.277, issue.49, pp.47954-47963, 2002. ,
DOI : 10.1074/jbc.M205156200
New mutations and pathogenesis of myeloproliferative neoplasms, Blood, vol.118, issue.7, pp.1723-1735, 2011. ,
DOI : 10.1182/blood-2011-02-292102
The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases, Blood, vol.111, issue.10, pp.4922-4929, 2008. ,
DOI : 10.1182/blood-2007-11-125328
Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis, Blood, vol.120, issue.25, pp.4921-4928, 2012. ,
DOI : 10.1182/blood-2011-09-376517
High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis, Leukemia, vol.131, issue.11, pp.2067-2070, 2006. ,
DOI : 10.1038/sj.leu.2404069
MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count, Haematologica, vol.91, p.57, 2006. ,
Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features, Leukemia, vol.87, issue.9, pp.1641-1644, 2006. ,
DOI : 10.1038/sj.leu.2404316
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia, Blood, vol.106, issue.10, pp.3370-3373, 2005. ,
DOI : 10.1182/blood-2005-05-1800
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders, Blood, vol.106, issue.6, pp.2162-2168, 2005. ,
DOI : 10.1182/blood-2005-03-1320
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes, Blood, vol.106, issue.4, pp.1207-1209, 2005. ,
DOI : 10.1182/blood-2005-03-1183
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes, Blood, vol.123, issue.10, pp.10-1182, 2013. ,
DOI : 10.1182/blood-2013-11-539098
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice, Blood, vol.111, issue.8, pp.3931-3940, 2008. ,
DOI : 10.1182/blood-2007-08-107748
Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease, Blood, vol.115, issue.17, pp.3589-3597, 2010. ,
DOI : 10.1182/blood-2009-04-215848
The JAK2V617F Mutation in Polycythemia Vera and Other Myeloproliferative Disorders: One Mutation for Three Diseases?, Hematology, vol.2008, issue.1, 2008. ,
DOI : 10.1182/asheducation-2008.1.69
Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis, New England Journal of Medicine, vol.356, issue.5, pp.459-468, 2007. ,
DOI : 10.1056/NEJMoa065202
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders, Blood, vol.111, issue.3, pp.1686-1689, 2008. ,
DOI : 10.1182/blood-2007-07-101576
Mutations in exon 12 of JAK2 are mainly found in JAK2 V617F-negative polycythaemia vera patients, British Journal of Haematology, vol.35, issue.4, pp.676-679, 2008. ,
DOI : 10.1111/j.1365-2141.2008.07223.x
The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels, Haematologica, vol.92, issue.12, pp.1607-1614, 2007. ,
DOI : 10.3324/haematol.11643
Phenotypic variations and new mutations in JAK2 V617F???negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis, Experimental Hematology, vol.35, issue.11, pp.1641-1646, 2007. ,
DOI : 10.1016/j.exphem.2007.08.010
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations, Blood, vol.117, issue.10, pp.2813-2816, 2011. ,
DOI : 10.1182/blood-2010-11-316810
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications, Leukemia, vol.22, issue.9, pp.1574-1579, 2010. ,
DOI : 10.1038/leu.2010.148
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel, Blood, vol.110, issue.4, pp.1092-1097, 2007. ,
DOI : 10.1182/blood-2007-04-083501
MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia, PLoS Medicine, vol.102, issue.7, p.270, 2006. ,
DOI : 10.1371/journal.pmed.0030270.st001
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients, Blood, vol.108, issue.10, pp.3472-3476, 2006. ,
DOI : 10.1182/blood-2006-04-018879
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia, Blood, vol.112, issue.3, pp.844-847, 2008. ,
DOI : 10.1182/blood-2008-01-135897
mutation, British Journal of Haematology, vol.365, issue.3, pp.244-247, 2007. ,
DOI : 10.1182/blood-2002-04-1199
URL : https://hal.archives-ouvertes.fr/hal-00535077
Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis, Haematologica, vol.94, issue.1, pp.141-144, 2009. ,
DOI : 10.3324/haematol.13224
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort, Blood, vol.112, issue.1, pp.141-149, 2008. ,
DOI : 10.1182/blood-2008-01-131664
Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin, Blood, vol.103, issue.11, pp.4198-4200, 2004. ,
DOI : 10.1182/blood-2003-10-3471
Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia, Haematologica, vol.94, issue.10, pp.1368-1374, 2009. ,
DOI : 10.3324/haematol.2009.005918
Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis, Blood, vol.110, issue.10, pp.3735-3743, 2007. ,
DOI : 10.1182/blood-2007-05-089003
W515 Mutation Analysis to Single Hematopoietic Colonies and B and T Lymphocytes, STEM CELLS, vol.131, issue.9, pp.2358-2362, 2007. ,
DOI : 10.1634/stemcells.2007-0175
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia, Blood, vol.123, issue.10, 2013. ,
DOI : 10.1182/blood-2013-11-538983
in Myeloid Cancers, New England Journal of Medicine, vol.360, issue.22, pp.2289-2301, 2009. ,
DOI : 10.1056/NEJMoa0810069
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis, Leukemia, vol.22, issue.5, pp.905-911, 2009. ,
DOI : 10.1038/leu.2009.47
in the Leukemic Transformation of Myeloproliferative Neoplasms, New England Journal of Medicine, vol.362, issue.4, pp.369-370, 2010. ,
DOI : 10.1056/NEJMc0910063
IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms, Leukemia, vol.28, issue.6, pp.1146-1151, 2010. ,
DOI : 10.1084/jem.20092506
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis, Leukemia, vol.114, issue.7, pp.1302-1309, 2010. ,
DOI : 10.1182/blood-2008-12-194548
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders, Nature Genetics, vol.8, issue.8, pp.722-726, 2010. ,
DOI : 10.1016/j.molcel.2008.10.016
EZH2 mutational status predicts poor survival in myelofibrosis, Blood, vol.118, issue.19, pp.5227-5234, 2011. ,
DOI : 10.1182/blood-2011-06-363424
Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms, Leukemia, vol.25, issue.7, pp.1200-1202, 2011. ,
DOI : 10.1182/blood-2010-06-293415
Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases, Journal of Hematology & Oncology, vol.5, issue.1, p.12, 2012. ,
DOI : 10.1182/blood-2009-07-235358
URL : https://hal.archives-ouvertes.fr/inserm-00698796
Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes, Haematologica, vol.96, issue.10, pp.1462-1469, 2011. ,
DOI : 10.3324/haematol.2011.045591
DNMT3A mutations in myeloproliferative neoplasms, Leukemia, vol.25, issue.7, pp.1217-1219, 2011. ,
DOI : 10.1056/NEJMoa1005143
DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms, Leukemia, vol.25, issue.7, pp.1219-1220, 2011. ,
DOI : 10.1182/blood-2009-09-245837
Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes, Blood Cancer Journal, vol.24, issue.5, p.18, 2011. ,
DOI : 10.1038/bcj.2011.15
SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival, Blood, vol.120, issue.20, pp.4168-4171, 2012. ,
DOI : 10.1182/blood-2012-05-429696
SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients, Leukemia, vol.3, issue.5, pp.1135-1137, 2012. ,
DOI : 10.1038/leu.2011.320
U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype, Leukemia, vol.119, issue.2, pp.431-433, 2014. ,
DOI : 10.1038/leu.2013.286
Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms, Blood, vol.113, issue.24, pp.6182-6192, 2009. ,
DOI : 10.1182/blood-2008-12-194548
Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases, Haematologica, vol.97, issue.12, pp.1890-1894, 2012. ,
DOI : 10.3324/haematol.2012.065375
CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2, Haematologica, vol.97, issue.8, pp.1234-1241, 2012. ,
DOI : 10.3324/haematol.2011.052605
Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F, Journal of Leukocyte Biology, vol.85, issue.6, pp.957-965, 2009. ,
DOI : 10.1189/jlb.0908575
Mutation???Negative Erythrocytosis, New England Journal of Medicine, vol.363, issue.12, pp.1189-1190, 2010. ,
DOI : 10.1056/NEJMc1006966
LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations, Leukemia, vol.118, issue.10, pp.1713-1718, 2010. ,
DOI : 10.1158/0008-5472.CAN-09-3783
Deletions of the transcription factor Ikaros in myeloproliferative neoplasms, Leukemia, vol.85, issue.7, pp.1290-1298, 2010. ,
DOI : 10.1073/pnas.0811761106
Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm, Blood, vol.115, issue.14, pp.2891-2900, 2010. ,
DOI : 10.1182/blood-2009-08-236596
p53 Lesions in Leukemic Transformation, p53 Lesions in Leukemic Transformation, pp.488-490, 2011. ,
DOI : 10.1056/NEJMc1012718
Cellular Functions of Endoplasmic Reticulum Chaperones Calreticulin, Calnexin, and ERp57, International Review of Cytology, vol.245, pp.91-121, 2005. ,
DOI : 10.1016/S0074-7696(05)45004-4
Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum, Biochemical Journal, vol.417, issue.3, p.651, 2009. ,
DOI : 10.1042/BJ20081847
Calnexin, Calreticulin, and ERp57: Teammates in Glycoprotein Folding, Cell Biochemistry and Biophysics, vol.39, issue.3, pp.223-247, 2003. ,
DOI : 10.1385/CBB:39:3:223
Quality control in the endoplasmic reticulum, Nature Reviews Molecular Cell Biology, vol.418, issue.3 ,
DOI : 10.1038/nrm1052
Beyond lectins: the calnexin/calreticulin chaperone system of the endoplasmic reticulum, Journal of Cell Science, vol.119, issue.4, pp.615-623, 2006. ,
DOI : 10.1242/jcs.02856
Calreticulin: non-endoplasmic reticulum functions in physiology and disease, The FASEB Journal, vol.24, issue.3, pp.665-683, 2010. ,
DOI : 10.1096/fj.09-145482
Calreticulin and Cancer, Pathology & Oncology Research, vol.174, issue.2, pp.149-154, 2013. ,
DOI : 10.1007/s12253-012-9600-2
Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47, Science Translational Medicine, vol.2, issue.63, pp.63-94, 2010. ,
DOI : 10.1126/scitranslmed.3001375
Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes, Proceedings of the National Academy of Sciences, vol.110, issue.8, pp.3011-3016, 2013. ,
DOI : 10.1073/pnas.1222861110
CBFB-SMMHC is correlated with increased calreticulin expression and suppresses the granulocytic differentiation factor CEBPA in AML with inv(16), Blood, vol.106, issue.4, pp.1369-1375, 2005. ,
DOI : 10.1182/blood-2004-11-4392
The leukemic fusion gene AML1-MDS1-EVI1 suppresses CEBPA in acute myeloid leukemia by activation of Calreticulin, Proceedings of the National Academy of Sciences, vol.101, issue.36, pp.13312-13317, 2004. ,
DOI : 10.1073/pnas.0404731101
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms, New England Journal of Medicine, vol.369, issue.25, pp.2379-2390, 2013. ,
DOI : 10.1056/NEJMoa1311347
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons, Leukemia, vol.26, issue.7, 2014. ,
DOI : 10.1038/leu.2014.3
Calreticulin mutations and long-term survival in essential thrombocythemia, Leukemia, vol.120, issue.12, 2014. ,
DOI : 10.1038/leu.2014.148
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients, American Journal of Hematology, vol.33, issue.8, pp.121-124, 2014. ,
DOI : 10.1002/ajh.23743
Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis, Leukemia, vol.91, issue.6, 2014. ,
DOI : 10.3324/haematol.13224
CALR mutations are infrequent in WHO-defined refractory anemia with ring sideroblasts, Leukemia, vol.87, issue.6, pp.1370-1371, 2014. ,
DOI : 10.1038/leu.2011.320
Calreticulin mutation was rarely detected in patients with myelodysplastic syndrome, Leukemia, vol.12, issue.7, 2014. ,
DOI : 10.1038/leu.2014.71
mutations are rare in childhood essential thrombocythemia, Pediatric Blood & Cancer, vol.369, issue.8, p.1523, 2014. ,
DOI : 10.1002/pbc.24984
CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence, Blood, vol.123, issue.23, pp.3677-3679, 2014. ,
DOI : 10.1182/blood-2014-04-572040
CALR mutation screening in pediatric primary myelofibrosis, Pediatric Blood & Cancer, vol.68, issue.12, 2014. ,
DOI : 10.1002/pbc.25211
Somatic mutations in calreticulin can be found in pedigrees with familial predisposition to myeloproliferative neoplasms, Blood, vol.123, issue.17, pp.2744-2745, 2014. ,
DOI : 10.1182/blood-2014-01-550863
Looking for CALR mutations in familial myeloproliferative neoplasms, Leukemia, vol.2, issue.6, pp.1357-1360, 2014. ,
DOI : 10.1182/blood-2007-04-083501
CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis, Blood, vol.123, issue.15, pp.2416-2419, 2014. ,
DOI : 10.1182/blood-2014-01-550434
Role of calreticulin mutations in the etiological diagnosis of splanchnic vein thrombosis, J. Hepatol, 2014. ,
Incidence of CALR mutations in patients with splanchnic vein thrombosis, Br. J. Haematol, 2014. ,
Bioinformatic analyses of CALR mutations in myeloproliferative neoplasms support a role in signaling, Leukemia, vol.103, issue.10, 2014. ,
DOI : 10.1038/leu.2014.190
Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis, Leukemia, vol.88, issue.5, pp.1152-1154, 2014. ,
DOI : 10.1111/j.1365-2141.2010.08122.x
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms, Blood, vol.123, issue.14, pp.2220-2228, 2014. ,
DOI : 10.1182/blood-2013-11-537167
Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact, Leukemia, vol.114, issue.7, pp.1568-1570, 2014. ,
DOI : 10.1038/leu.2014.83
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis, Blood, vol.124, issue.16, pp.10-1182, 2014. ,
DOI : 10.1182/blood-2014-05-579136
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients, Leukemia, vol.122, issue.9, 2014. ,
DOI : 10.1038/leu.2014.76
Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation, Leukemia, vol.115, issue.7, 2014. ,
DOI : 10.1038/leu.2014.66
CALR versus JAK2 mutated essential thrombocythaemia ? a report on 141 patients, Br. J. Haematol, 2014. ,
Clinical importance of different calreticulin gene mutation types in wildtype JAK2 essential thrombocythemia and myelofibrosis patients, Haematologica, 2014. ,
Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations, Haematologica, vol.99, issue.7, pp.1184-1190, 2014. ,
DOI : 10.3324/haematol.2014.107482
Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia, Annals of Hematology, vol.117, issue.12, 2014. ,
DOI : 10.1007/s00277-014-2151-8
CALR and ASXL1 mutation analysis in 190 patients with essential thrombocythemia, Leuk. Lymphoma, vol.1, issue.9, 2014. ,
Calreticulin mutations in Chinese with primary myelofibrosis, Haematologica, vol.99, issue.11, 2014. ,
DOI : 10.3324/haematol.2014.109249
Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution, Leukemia, vol.29, issue.1, 2014. ,
DOI : 10.1182/blood-2014-02-554634
URL : https://hal.archives-ouvertes.fr/hal-01258918
CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients, Leukemia, vol.54, issue.7, pp.1494-1500, 2014. ,
DOI : 10.1038/leu.2014.57
-Mutated Essential Thrombocythemia, New England Journal of Medicine, vol.371, issue.2, pp.188-189, 2014. ,
DOI : 10.1056/NEJMc1401255
URL : https://hal.archives-ouvertes.fr/hal-01276534
JAK inhibitor in CALR?mutant myelofibrosis, N. Engl. J. Med, vol.370, pp.1168-1169, 2014. ,
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value, Leukemia, vol.277, issue.9, 2014. ,
DOI : 10.1038/leu.2014.100
Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders, Leukemia, vol.366, issue.6, pp.1181-1183, 2006. ,
DOI : 10.1038/sj.leu.2404214
The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera, Blood, vol.108, issue.6, pp.1865-1867, 2006. ,
DOI : 10.1182/blood-2006-01-013540
A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms, Annals of Hematology, vol.110, issue.4, pp.609-616, 2014. ,
DOI : 10.1007/s00277-013-1920-0
Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression, Blood, vol.108, issue.12, pp.3913-3915, 2006. ,
DOI : 10.1182/blood-2006-03-008805
A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis, Leukemia, vol.365, issue.6, pp.1331-1332, 2007. ,
DOI : 10.1038/sj.leu.2404214
Identification of an Acquired JAK2 Mutation in Polycythemia Vera, Journal of Biological Chemistry, vol.280, issue.24 ,
DOI : 10.1074/jbc.C500138200
A quantitative assay for JAK2V617F mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis, Leukemia, vol.127, issue.6, pp.1055-1060, 2006. ,
DOI : 10.1038/sj.leu.2404209
JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets, British Journal of Haematology, vol.41, issue.3, pp.64-69, 2007. ,
DOI : 10.1111/j.1365-2141.2005.05764.x
Guideline for investigation and management of adults and children presenting with a thrombocytosis, British Journal of Haematology, vol.100, issue.Suppl 1, pp.352-375, 2010. ,
DOI : 10.1111/j.1365-2141.2010.08122.x
The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis ??? impact on disease phenotype, European Journal of Haematology, vol.365, issue.6, pp.508-515, 2007. ,
DOI : 10.1038/sj.leu.2404209
JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone, Blood, vol.120, issue.13, pp.2704-2707, 2012. ,
DOI : 10.1182/blood-2012-05-431791
X chromosome inactivation analysis reveals a difference in the biology of ET patients with JAK2 and CALR mutations, Blood, vol.124, issue.13, pp.10-1182, 2014. ,
DOI : 10.1182/blood-2014-06-580183
Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders, Blood, vol.108, issue.4, pp.1377-1380, 2006. ,
DOI : 10.1182/blood-2005-11-009605
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia, Blood, vol.110, issue.3, pp.840-846, 2007. ,
DOI : 10.1182/blood-2006-12-064287
Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival, Leukemia, vol.22, issue.4, pp.756-761, 2008. ,
DOI : 10.1038/sj.leu.2404750
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele, Blood, vol.114, issue.8, pp.1477-1483, 2009. ,
DOI : 10.1182/blood-2009-04-216044
Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden, Leukemia, vol.290, issue.9, pp.1952-1959, 2007. ,
DOI : 10.1182/blood-2006-03-009860
JAK2V617F allele burden and thrombosis: A direct comparison in essential thrombocythemia and polycythemia vera, Experimental Hematology, vol.37, issue.9, pp.1016-1021, 2009. ,
DOI : 10.1016/j.exphem.2009.06.006
allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment, Therapeutic Advances in Hematology, vol.1, issue.1, pp.21-32, 2011. ,
DOI : 10.1182/blood-2005-09-3900
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis, Blood, vol.107, issue.5, pp.2098-2100, 2006. ,
DOI : 10.1182/blood-2005-08-3395
URL : https://hal.archives-ouvertes.fr/hal-00453286
The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates, British Journal of Haematology, vol.59, issue.3, pp.320-328, 2005. ,
DOI : 10.1074/jbc.C500138200
JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis, Blood, vol.110, issue.12, pp.4030-4036, 2007. ,
DOI : 10.1182/blood-2007-07-099184
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele, Blood, vol.114, issue.8, pp.1477-1483, 2009. ,
DOI : 10.1182/blood-2009-04-216044
Assessment of CALR mutations in myelofibrosis patients, post?allogeneic stem cell transplantation ,
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera, Blood, vol.112, issue.8, pp.3065-3072, 2008. ,
DOI : 10.1182/blood-2008-03-143537
Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy, Haematologica, vol.93, issue.11, pp.1723-1727, 2008. ,
DOI : 10.3324/haematol.13081
Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis, Blood, vol.116, issue.18, pp.3572-3581, 2010. ,
DOI : 10.1182/blood-2009-12-260588
Clinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden at diagnosis, Haematologica, vol.99, issue.7, pp.98-101, 2014. ,
DOI : 10.3324/haematol.2014.107656
URL : https://hal.archives-ouvertes.fr/inserm-01402419
Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2(V617F), Leukemia, vol.21, pp.1128-1130, 2007. ,
Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis, Blood, vol.109, issue.1, pp.71-77, 2007. ,
DOI : 10.1182/blood-2006-03-007146
Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera, Blood, vol.108, issue.9, pp.3128-3134, 2006. ,
DOI : 10.1182/blood-2006-04-017392
Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations, Blood, vol.111, issue.7, pp.3863-3866, 2008. ,
DOI : 10.1182/blood-2007-09-111971
Allelic Expression Imbalance of JAK2 V617F Mutation in BCR-ABL Negative Myeloproliferative Neoplasms, PLoS ONE, vol.106, issue.1, p.52518, 2013. ,
DOI : 10.1371/journal.pone.0052518.s008